that would be high on the list for off label use IMO. It's not like you have to inject deep like for many other therapeutic indications I also think they prioritize a larger opportunity within therapeutics first in terms of trials
Hyperhidrosis is a tiny portion of the therapeutics market for botulinum toxin, so I don't think RVNC can justify the cost of running clinical trials in that indication. Daxxify will get some off-label sales for hyperhidrosis even without clinical data, as dewophile just said.
RVNC tested its (now discontinued) topical toxin formulation in hyperhidrosis, but the trial was a failure (#msg-119391369).
Market Data 
Markets 
AI
